Clinipace Worldwide, the CRO headquartered in Research Triangle Park, North Carolina, has announced that 2013 was its strongest year to date. New clinical development projects and regulatory and strategic development engagements accounted for 114% growth in bookings compared to 2012, according to the company.
Clinipace reported 63% growth in consolidated revenues, plus 194% year-on-year growth in new bookings for full-service studies and a tripling of average contract value. It experienced solid growth in several therapeutic areas, including oncology/hematology, infectious disease, gastroenterology, cardiovascular, nephrology, immunology, pediatrics, and women’s health. One of the company’s areas of specialty is managing oncology clinical trials.
The firm hired 50 net new team members in 2013, and expects to expand by an additional 25% in 2014, especially in clinical monitoring, site management services, clinical project management, clinical data management, and financial operations.
Outside of the U.S., the CRO’s offices are located in Zurich (Switzerland), Munich (Germany), High Wycombe (U.K.), Tel-Aviv (Israel), Sao Paulo (Brazil), Buenos Aires (Argentina), and Trivandrum Kerala and New Delhi (India).
Read the full release here.